Recent evidence has highlighted the therapeutic capacity of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), already employed in treating T2DM and obesity, in modulating systemic and intestinal inflammatory responses. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.